Department of Anesthesiology
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Deon D, Ahmed S, Tai K, Scaletta N, Herrero C, Lee IH, Krause A, Ivashkiv LB.  2001.  Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts.. J Immunol. 167(9):5395-403.
Kim J-H, Pandit N, Yoo M, Park THyun, Choi JU, Park CHoon, Jung K-Y, Lee BIl.  2023.  Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.. Sci Rep. 13(1):10805.
Bae E, Bitto E, Bingman CA, McCoy JG, Wesenberg GE, Phillips GN.  2010.  Crystal structure of an eIF4G-like protein from Danio rerio.. Proteins. 78(7):1803-6.
Bailey LJ, Acheson JF, McCoy JG, Elsen NL, Phillips GN, Fox BG.  2012.  Crystallographic analysis of active site contributions to regiospecificity in the diiron enzyme toluene 4-monooxygenase.. Biochemistry. 51(6):1101-13.
Donlon JV, Savarese JJ, Ali HH.  1979.  Cumulative dose-response curves for gallamine: effect of altered resting thumb tension and mode of stimulation.. Anesth Analg. 58(5):377-81.
Lien CA, Kopman AF.  2014.  Current recommendations for monitoring depth of neuromuscular blockade.. Curr Opin Anaesthesiol. 27(6):616-22.
Chambers TAnn, Bagai A, Ivascu N.  2007.  Current trends in coronary artery disease in women.. Curr Opin Anaesthesiol. 20(1):75-82.
Pan S, Gries K, Engel BD, Schroda M, Haselwandter CA, Scheuring S.  2024.  The cyanobacterial protein VIPP1 forms ESCRT-III-like structures on lipid bilayers.. Nat Struct Mol Biol.
Brezina V, Proekt A, Weiss KR.  2006.  Cycle-to-cycle variability as an optimal behavioral strategy.. Neurocomputing. 69(10-12):1120-1124.
Horn CC, Zhurov Y, Orekhova IV, Proekt A, Kupfermann I, Weiss KR, Brezina V.  2004.  Cycle-to-cycle variability of neuromuscular activity in Aplysia feeding behavior.. J Neurophysiol. 92(1):157-80.
Nimigean CM, Shane T, Miller C.  2004.  A cyclic nucleotide modulated prokaryotic K+ channel.. J Gen Physiol. 124(3):203-10.
Sunaga H, Malhotra JK, Yoon E, Savarese JJ, Heerdt PM.  2010.  Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology.. Anesthesiology. 112(4):900-9.
D
Hotte M, Thuault S, Lachaise F, Dineley KT, Hemmings HC, Nairn AC, Jay TM.  2006.  D1 receptor modulation of memory retrieval performance is associated with changes in pCREB and pDARPP-32 in rat prefrontal cortex.. Behav Brain Res. 171(1):127-33.
Park JK, Yale-Loehr S, Kaur G.  2023.  DACA, public health, and immigrant restrictions on healthcare in the United States.. Lancet Reg Health Am. 21:100493.
Hemmings HC, Nairn AC, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1.. J Biol Chem. 259(23):14491-7.
Hemmings HC, Williams KR, Konigsberg WH, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. I. Amino acid sequence around the phosphorylated threonine.. J Biol Chem. 259(23):14486-90.
Ouimet CC, Miller PE, Hemmings HC, Walaas SI, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization.. J Neurosci. 4(1):111-24.
Hemmings HC, Nairn AC, Aswad DW, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus.. J Neurosci. 4(1):99-110.
Hemmings HC, Greengard P.  1986.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein: regional, tissue, and phylogenetic distribution.. J Neurosci. 6(5):1469-81.
Williams KR, Hemmings HC, LoPresti MB, Konigsberg WH, Greengard P.  1986.  DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. Primary structure and homology with protein phosphatase inhibitor-1.. J Biol Chem. 261(4):1890-903.
Hemmings HC, Greengard P, Tung HY, Cohen P.  1984.  DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.. Nature. 310(5977):503-5.
Hemmings HC, Greengard P.  1986.  DARPP-32, a dopamine-regulated phosphoprotein.. Prog Brain Res. 69:149-59.
Nairn AC, Hemmings HC, Walaas SI, Greengard P.  1988.  DARPP-32 and phosphatase inhibitor-1, two structurally related inhibitors of protein phosphatase-1, are both present in striatonigral neurons.. J Neurochem. 50(1):257-62.
Hökfelt T, Foster G, Schultzberg M, Meister B, Schalling M, Goldstein M, Hemmings HC, Ouimet C, Greengard P.  1988.  DARPP-32 as a marker for D-1 dopaminoceptive cells in the rat brain: prenatal development and presence in glial elements (tanycytes) in the basal hypothalamus.. Adv Exp Med Biol. 235:65-82.
Matovcik LM, Hemmings HC, Kinder BK.  1995.  DARPP-32 (dopamine and cAMP-regulated phosphoprotein, M(r) 32,000) is a membrane protein in the bovine parathyroid.. FEBS Lett. 364(1):67-74.